G1 Therapeutics

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

G1 Therapeutics excels in Q4 with Cosela sales surge and optimistic 2023 outlook

G1 Therapeutics delivered strong financial results in Q4 2022, driven by the impressive performance of Cosela in the small cell lung cancer market. Despite organizational changes to conserve capital, the company remains focused on growth and innovation. With a solid cash balance projection for 2023 and a growing customer base, G1 Therapeutics is poised for continued success.

G1 Therapeutics reports robust Q1 performance and optimistic growth outlook

G1 Therapeutics demonstrated strong financial performance and commercial growth in Q1 2023, with COSELA showing promising results and a positive outlook for the future.
While facing challenges related to potential drug interactions, the company is well-positioned to capitalize on opportunities through upcoming data readouts and strategic decisions.
Investors can be optimistic about G1 Therapeutics' continued progress, supported by a solid financial foundation and a focus on maximizing COSELA's potential.

G1 Therapeutics reports resilient Q2 performance amidst challenges and opportunities

G1 Therapeutics delivered a strong financial performance in Q2 2023, showcasing resilience and strategic financial management amidst challenges.
The company's focus on advancing its clinical pipeline and securing survival results in early 2024 positions it for future growth and value creation.
While facing challenges such as a chemotherapy shortage and operational efficiency, G1 Therapeutics maintains stability and confidence in its financial outlook.
Opportunities lie in capitalizing on COSELA sales growth, advancing clinical programs, and leveraging financial flexibility for sustained growth and innovation.

G1 Therapeutics overcomes supply challenges, eyes growth in oncology

G1 Therapeutics exhibited resilience in revenue growth despite challenges with COSELA's market supply, showcasing operational strength.
The company's strong financial position and cost management efforts bode well for sustainable growth and value creation.
Exciting opportunities in clinical trials and market expansion present avenues for future success and competitive positioning in the oncology sector.

G1 Therapeutics excels in Q4 2023, poised for growth ahead

G1 Therapeutics demonstrated strong performance in Q4 2023 with notable revenue growth and expense management.
COSELA's market share and promising trial results highlight strengths in the product portfolio.
While challenges like trial result anticipation and cost efficiency persist, opportunities for growth and optimization are evident.
Overall, G1 Therapeutics shows promise with a healthy cash position and positive sales guidance for 2024.

G1 Therapeutics reports strong Q1 earnings and diversifies revenue streams

G1 Therapeutics delivered robust financial results, showcasing growth in revenue and cost management improvements in Q1 2024.
While facing challenges in managing expenses and advancing clinical trials, the company remains optimistic about revenue guidance and market opportunities.
With a solid cash position and strategic partnerships, G1 Therapeutics is well-positioned to drive future growth and innovation in the oncology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

G1 Therapeutics, Inc. is a commercial-stage oncology firm focused on the research and marketing of next-generation anticancer treatments.

RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it is supporting a Phase 2 investigator initiated study (ISS) of trilaciclib and lurbinectedin in patients with extensive stage small cell lung cancer (ES-SCLC). An ISS is a study that is proposed, developed, and conducted by a qualified sponsor external to G1 Therapeutics who assumes full responsibility for the conduct of the study.

G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer

Though no longer having Boehringer as its launch partner, G1 Therapeutics, Inc. posted good sales traction for Cosela. There are several big data releases going into the year-end and next year that can significantly move the needle on this stock.

G1 Therapeutics: Catalysts Stacking

RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2022 on Wednesday, November 2, 2022, at 8:30 a.m. ET.

G1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022

Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.

Is G1 Therapeutics (GTHX) Outperforming Other Medical Stocks This Year?

RESEARCH TRIANGLE PARK, N.C., Oct. 10, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the last patient has been randomized in PRESERVE 2, G1's Phase 3 clinical trial of trilaciclib in patients with metastatic triple negative breast cancer (TNBC) receiving chemotherapy. The trial includes 187 patients receiving first line trilaciclib or placebo prior to gemcitabine and carboplatin (GC).

G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)

Apple

Alector Inc

Caterpillar

Celsius Holdings

Clearfield

Invesco Treasury Collateral ETF

Chevron

Dow Inc

Enphase Energy

Alphabet

Intrepid Potash

Johnson & Johnson

JPMorgan Chase & Co

McDonald's

Merck

Microsoft

Direxion Daily Semiconductor Bull 3x Shares

SPDR S&P 500 ETF Trust

TravelCenters of America

Tidewater

Direxion Daily Utilities Bull 3X Shares

Viridian Therapeutics

Wave Life Sciences

Zymeworks Inc

Two new Breakout Stocks for Week 40 with better than 10% short-term upside potential and one Dow 30 pick. Average cumulative returns now up to +105.6% YTD. This week 2 picks beat 10% in less than a week with FUSN +12.2%, LRMR at +12.95% and VYGR +9.2% peak gains continuing in high negative Momentum Gauge warnings.

MDA Breakout Stocks Week 40 - October 2022: Short-Term Picks To Give You An Edge

Today, we put G1 Therapeutics, Inc. in the spotlight. The company's main asset is COSELA, a small-molecule, short-acting, inhibitor of cyclin-dependent kinases 4 and 6.

G1 Therapeutics: Building A Franchise

RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1's Chief Executive Officer, and other members of the executive team will participate virtually in the H.C. Wainwright 24th Annual Global Investment Conference. The fireside chat with G1 will be available at 7:00AM ET on September 12, 2022. The webcast and replay of this event will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

G1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual Global Investment Conference

RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will host a virtual R&D Day, “Innovations in Oncology: The Science of Trilaciclib”, on Thursday, September 15, 2022, from 9:00 a.m. to 11:00 a.m. ET.

G1 Therapeutics to Host Virtual R&D Day on September 15, 2022

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

G1 Therapeutics (GTHX)'s Technical Outlook is Bright After Key Golden Cross

The mean of analysts' price targets for G1 Therapeutics (GTHX) points to a 149.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can G1 Therapeutics (GTHX) Climb 150% to Reach the Level Wall Street Analysts Expect?

Symbotic Inc. (SYM) Q3 2022 Earnings Conference Call August 1, 2022 5:00 PM ET Company Participants Will Roberts - Head-Corporate Communications Jack Bailey - CEO Jen Moses - CFO Andrew Perry - Chief Commercial Officer Raj Malik - Chief Medical Officer Conference Call Participants Gil Blum - Needham & Company Kaveri Pohlman - BTIG Tony Butler - ROTH Capital Edward White - H.C. Wainwright David Nierengarten - Wedbush Securities Anupam Rama - JPMorgan Troy Langford - Cowen Operator Good day, and thank you for standing by.

G1 Therapeutics, Inc. (GTHX) CEO Jack Bailey on Q1 2022 Results - Earnings Call Transcript

- Achieved $8.7 Million in Net Revenue from Sales of COSELA® (trilaciclib) in the Second Quarter of 2022 and $10.6 Million in Total Revenue -

G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights

RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences in August 2022.

G1 Therapeutics to Participate Virtually in the 2022 BTIG Biotechnology Conference and the 2022 Wedbush Pacgrow Healthcare Conference

G1 Therapeutics (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate G1 Therapeutics (GTHX) to Report a Decline in Earnings: What to Look Out for

RESEARCH TRIANGLE PARK, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Norman E. “Ned” Sharpless, M.D., to its Board of Directors. For nearly 30 years, Dr. Sharpless has been committed to the fight against cancer, including serving as one of the scientific founders of G1 in 2008. He is an accomplished oncologist and seasoned public servant who has treated cancer patients, investigated the biologic basis of cancer, and has led academic institutions and government agencies, including most recently serving as Director of the National Cancer Institute (NCI) at the National Institutes of Health.

G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors

GTHX will topline the mCRC phase 3 trial in November. This will help expand its label and increase revenues.

G1 Therapeutics: Take Advantage Of The November Data

RESEARCH TRIANGLE PARK, N.C., July 20, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2022 on Wednesday, August 3, 2022, at 8:30 a.m. ET.

G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022

RESEARCH TRIANGLE PARK, N.C., July 13, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the China National Medical Products Administration (NMPA) has conditionally approved COSELA (trilaciclib hydrochloride for injection), which was jointly developed for use in Greater China by Simcere and G1 Therapeutics. COSELA is now indicated in China to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer. As a result of receiving approval in China, G1 will receive a $13 million milestone payment. In total, G1 may receive up to $156M in total milestones. G1 may also receive double-digit royalties on annual net sales of COSELA in China.

COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Adaptimmune Therapeutics

Axsome Therapeutics

Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.

Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket

RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Jacks Lee to its Board of Directors. For more than 30 years, Mr. Lee has developed extensive experience in manufacturing and supply chain management in the life sciences industry. Mr. Lee currently serves as Senior Vice President – Manufacturing & Supply of Merck & Co., Inc., a global premier research-intensive biopharmaceutical health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products.

G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors

Initial Data Expected in Early 2023 Including the Primary Endpoint of Myeloprotection Initial Data Expected in Early 2023 Including the Primary Endpoint of Myeloprotection

G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer

- Patients Receiving Trilaciclib Experienced a Lower Incidence of Single-Lineage and Multilineage Chemotherapy-Induced Myelosuppressive Events Compared with Patients Receiving Placebo -

Data Presented at ASCO Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, and Severe Thrombocytopenia When Given to Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients Prior to Chemotherapy

RESEARCH TRIANGLE PARK, N.C., May 20, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it received Triangle Business Journal's 2022 Company of the Year (Public) award, one of two such awards presented at the 2022 Life Sciences Award ceremony.

G1 Therapeutics Named 2022 Life Sciences Public Company of the Year by Triangle Business Journal

RESEARCH TRIANGLE PARK, N.C., May 18, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1's Chief Executive Officer, will provide a virtual corporate presentation during the H.C. Wainwright & Co. Global Investment Conference. The presentation will become available at 7:00 AM EDT on May 24, 2022. This meeting is being held in person and virtually; the webcast of G1's presentation will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

News for G1 Therapeutics Stock (GTHX)